Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02640339 · ClinicalTrials.gov registry record
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 166
- Enrollment target
NCT02640339 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 166 participants.
The verdict
NCT02640339 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 166 participants
- Enrollment target
Study Summary
* To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime in patients with Parkinson disease. * To establish whether these measures can be used to identify patients with PD in the premotor phase. * To define the rate of progression of retinal abnormalities in PD (both in the motor and premotor stages) for potential use as a clinical outcome measure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02640339
The ClinicalTrials.gov registry entry for NCT02640339 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02640339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02640339 about?
NCT02640339 is a clinical study titled "Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease". * To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime in patients with Parkinson disease. * To establish whether these meas...
What is the current status of trial NCT02640339?
This trial is currently completed. The enrollment target is 166 participants. The study started on 2016-02. Estimated completion is 2020-10-31.
Who is sponsoring clinical trial NCT02640339?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.